NALOXONE HYDROCHLORIDE | A211951 | PADAGIS ISRAEL PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
ADAPT PHARMA OPERATIONS LIMITED et al v. PERRIGO UK FINCO LIMITED PARTNERSHIP 1 patentANDA 211951naloxone hydrochloride | D.N.J. | 2018-12-07 | Terminated 2019-05-03 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$16.92
per ea
Lowest NADAC/Unit
$16.92
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 46122081271GNP NALOXONE HCL 4 MG NASAL SP | $16.92 | EA | Generic | — | 2026-08-19 |
| 45802057884NALOXONE HCL 4 MG NASAL SPRAY | $16.92 | EA | Generic | — | 2026-08-19 |
| 68001064545NALOXONE HCL 4 MG NASAL SPRAY | $16.92 | EA | Generic | — | 2026-08-19 |
| 70677128301FT NALOXONE HCL 4 MG NASAL SPR | $16.92 | EA | Generic | — | 2026-08-19 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.